---
title: "Merck & Co., Inc., Rahway, NJ, USA (United States)"
description: "From 2017 to 2026 (so far), authors at Merck & Co., Inc., Rahway, NJ, USA (United States) took part in 62 papers in the tracked journals, most of them in health economics and policy (50), statistics (9) and AI (2). 5 of them were published in 2025, against 4 in 2017."
url: https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states
markdown_url: https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Merck & Co., Inc., Rahway, NJ, USA (United States) took part in 62 papers in the tracked journals, most of them in health economics and policy (50), statistics (9) and AI (2). 5 of… (as of 2026-11-04)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-04T00:03:46+09:00
window: 2026-10-06 to 2026-11-04
source: OpenAlex (CC0)
---

# Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers in the tracked journals with an author at Merck & Co., Inc., Rahway, NJ, USA (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Merck & Co., Inc., Rahway, NJ, USA (United States) took part in 62 papers in the tracked journals, most of them in health economics and policy (50), statistics (9) and AI (2).
- 5 of them were published in 2025, against 4 in 2017.
- Since 2023, the institutions with the most of these papers were Adelphi Group (United Kingdom) (3), Analysis Group (United States) (3) and MSD (Switzerland) (3).
- The journals publishing most of them were PharmacoEconomics (6), PharmacoEconomics - Open (6) and Health Economics Review (3).
- The most-cited of them is “Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States” (PharmacoEconomics, 2017), with 142 citations.
- Since 2023, papers in the tracked journals cited 24 of its papers 56 times; 96% of those links came from papers with a university author and 14% from its own papers.
- Its own papers since 2023 cite archived papers 30 times, 53% of them papers with a company author.
- Across everything OpenAlex indexes, Merck & Co., Inc., Rahway, NJ, USA (United States) has 41,964 works with 9,396,899 citations (h-index 923).
- The tracked journals hold 53 of its 13,629 works in OpenAlex from 2017 to 2025 (0.4%).
- Its main research topics in OpenAlex are Cancer Immunotherapy and Biomarkers (2,973), Pharmacogenetics and Drug Metabolism (1,654) and Statistical Methods in Clinical Trials (1,589).

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 4 | 1 | 5 | 5 | 8 | 8 | 3 | 3 | 5 | 8 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 1 |
| [AI](https://scholar4ai.com/categories/ai.md) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| [Economics](https://scholar4ai.com/categories/economics.md) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| All categories | 4 | 3 | 5 | 6 | 10 | 11 | 4 | 5 | 5 | 9 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 6 |
| 2 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 6 |
| 3 | [Health Economics Review](https://scholar4ai.com/journals/health-economics-review.md) | 3 |
| 4 | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2 |
| 5 | [Computational Statistics & Data Analysis](https://scholar4ai.com/journals/computational-statistics-data-analysis.md) | 1 |
| 6 | [Statistical Papers](https://scholar4ai.com/journals/statistical-papers.md) | 1 |
| 7 | [Computational Statistics](https://scholar4ai.com/journals/computational-statistics.md) | 1 |
| 8 | [Health Research Policy and Systems](https://scholar4ai.com/journals/health-research-policy-and-systems.md) | 1 |
| 9 | [Cost Effectiveness and Resource Allocation](https://scholar4ai.com/journals/cost-effectiveness-and-resource-allocation.md) | 1 |
| 10 | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | Adelphi Group (United Kingdom) | 3 |
| 2 | [Analysis Group (United States)](https://scholar4ai.com/companies/analysis-group-united-states.md) | 3 |
| 3 | MSD (Switzerland) | 3 |
| 4 | [University of Sheffield](https://scholar4ai.com/institutions/university-of-sheffield.md) | 3 |
| 5 | Duke Medical Center | 2 |
| 6 | [Duke University](https://scholar4ai.com/institutions/duke-university.md) | 2 |
| 7 | MSD (UK) Limited (United Kingdom) | 2 |
| 8 | University of Arkansas for Medical Sciences | 2 |
| 9 | University of Maryland, Baltimore | 2 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United States | 23 |
| 2 | United Kingdom | 9 |
| 3 | Switzerland | 4 |
| 4 | Germany | 2 |
| 5 | Canada | 1 |
| 6 | China | 1 |
| 7 | Japan | 1 |
| 8 | Portugal | 1 |
| 9 | Sweden | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [quality-adjusted life years](https://scholar4ai.com/keywords/quality-adjusted-life-years.md) | 8 |
| 2 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 6 |
| 3 | [health care costs](https://scholar4ai.com/keywords/health-care-costs.md) | 5 |
| 4 | [economic burden](https://scholar4ai.com/keywords/economic-burden.md) | 4 |
| 5 | health utility | 4 |
| 6 | pulmonary arterial hypertension | 4 |
| 7 | [COVID-19 pandemic](https://scholar4ai.com/keywords/covid-19-pandemic.md) | 3 |
| 8 | adults | 3 |
| 9 | disease severity | 3 |
| 10 | [health technology assessment](https://scholar4ai.com/keywords/health-technology-assessment.md) | 3 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 142 | 1.3 | [Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States](https://doi.org/10.1007/s40273-017-0527-z) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-06-15 | Min Huang, Yanyan Lou, James M. Pellissier et al. |
| 2 | 46 | 0.8 | [Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review](https://doi.org/10.1007/s40273-021-01121-7) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2022-02-02 | Min Huang, Amin Haiderali, Grace E. Fox et al. |
| 3 | 43 | 0.4 | [Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis](https://doi.org/10.1007/s41669-017-0050-3) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2017-08-07 | Bernard H. Charbonnel, D. Simon, Jean Dallongeville et al. |
| 4 | 41 | 0.8 | [Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US](https://doi.org/10.1007/s40273-022-01168-0) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2022-07-01 | Hardik Goswami, Adnan Alsumali, Yiling Jiang et al. |
| 5 | 39 | 0.5 | [An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?](https://doi.org/10.1016/j.healthpol.2020.07.007) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2020-07-29 | Chiara L. Whichello, Karin Schölin Bywall, Jonathan Mauer et al. |
| 6 | 34 | 0.4 | [Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong](https://doi.org/10.1007/s41669-019-00178-7) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2019-09-17 | Herbert Ho-Fung Loong, Carlos King Ho Wong, Linda Kam Suet Leung et al. |
| 7 | 34 | 0.6 | [Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors](https://doi.org/10.1016/j.healthpol.2022.06.003) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2022-06-07 | Charlotte Poon, Artes Haderi, Alexander Roediger et al. |
| 8 | 32 | 0.4 | [Optimal control of prevention and treatment in a basic macroeconomic–epidemiological model](https://doi.org/10.1016/j.mathsocsci.2020.03.005) | [Mathematical Social Sciences](https://scholar4ai.com/journals/mathematical-social-sciences.md) | 2020-04-25 | Davide La Torre, Tufail M. Malik, Simone Marsiglio |
| 9 | 32 | 0.5 | [Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective](https://doi.org/10.1007/s40273-021-01091-w) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-10-08 | Adnan Alsumali, Laurence M. Djatche, Andrew H. Briggs et al. |
| 10 | 32 | 1.3 | [A call for an industry-led initiative to critically assess machine learning for real-world drug discovery](https://doi.org/10.1038/s42256-024-00911-w) | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 2024-10-04 | Cas Wognum, Jeremy R. Ash, Matteo Aldeghi et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | SKEMA Business School | University | France | 7 |
| 2 | [Université Côte d'Azur](https://scholar4ai.com/institutions/universite-cote-d-azur.md) | University | France | 7 |
| 3 | [University of Pisa](https://scholar4ai.com/institutions/university-of-pisa.md) | University | Italy | 6 |
| 4 | [University of Groningen](https://scholar4ai.com/institutions/university-of-groningen.md) | University | Netherlands | 5 |
| 5 | [University of Toronto](https://scholar4ai.com/institutions/university-of-toronto.md) | University | Canada | 4 |
| 6 | [University of Sheffield](https://scholar4ai.com/institutions/university-of-sheffield.md) | University | United Kingdom | 4 |
| 7 | [University of Alberta](https://scholar4ai.com/institutions/university-of-alberta.md) | University | Canada | 3 |
| 8 | University of Milan | University | Italy | 3 |
| 9 | [Erasmus University Rotterdam](https://scholar4ai.com/institutions/erasmus-university-rotterdam.md) | University | Netherlands | 3 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [University of Sheffield](https://scholar4ai.com/institutions/university-of-sheffield.md) | University | United Kingdom | 7 |
| 2 | University of Basel | University | Switzerland | 3 |
| 3 | [Analysis Group (United States)](https://scholar4ai.com/companies/analysis-group-united-states.md) | Company | United States | 3 |
| 4 | [The University of Melbourne](https://scholar4ai.com/institutions/the-university-of-melbourne.md) | University | Australia | 2 |
| 5 | [Duke University](https://scholar4ai.com/institutions/duke-university.md) | University | United States | 2 |
| 6 | Bielefeld University | University | Germany | 2 |
| 7 | [University of Oxford](https://scholar4ai.com/institutions/university-of-oxford.md) | University | United Kingdom | 2 |
| 8 | Office Of Health Economics | Government | United Kingdom | 2 |
| 9 | Duke Medical Center | Healthcare | United States | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## In OpenAlex

*Merck & Co., Inc., Rahway, NJ, USA (United States) in OpenAlex*

| Item | Value |
|---|---|
| Type | Company |
| Location | Rahway, New Jersey, United States |
| Also known as | MSD, MSD United States, Merck & Co., Inc., Rahway, NJ, USA |
| Units listed in OpenAlex | 29 |
| Works in OpenAlex | 41,964 |
| Citations | 9,396,899 |
| h-index | 923 |
| i10-index | 100,677 |
| 2-year mean citedness | 6.16 |
| Website | [www.merck.com](https://www.merck.com) |
| ROR | [ror.org/02891sr49](https://ror.org/02891sr49) |
| OpenAlex | [openalex.org/I1285764155](https://openalex.org/I1285764155) |

*Works and citations per year in OpenAlex, and its papers in the tracked journals*

| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---:|---:|---:|---:|
| 2026 (so far) | 1,313 | 99,904 | 9 | 0.7% |
| 2025 | 1,619 | 126,960 | 5 | 0.3% |
| 2024 | 1,678 | 131,370 | 5 | 0.3% |
| 2023 | 1,629 | 126,413 | 4 | 0.2% |
| 2022 | 1,677 | 125,614 | 11 | 0.7% |
| 2021 | 1,583 | 126,520 | 10 | 0.6% |
| 2020 | 1,599 | 112,690 | 6 | 0.4% |
| 2019 | 1,373 | 94,422 | 5 | 0.4% |
| 2018 | 1,258 | 86,973 | 3 | 0.2% |
| 2017 | 1,213 | 81,863 | 4 | 0.3% |

*Main research topics (OpenAlex, all works)*

| # | Topic | Field | Works |
|---:|---|---|---:|
| 1 | Cancer Immunotherapy and Biomarkers | Medicine | 2,973 |
| 2 | Pharmacogenetics and Drug Metabolism | Pharmacology, Toxicology and Pharmaceutics | 1,654 |
| 3 | Statistical Methods in Clinical Trials | Mathematics | 1,589 |
| 4 | Health Systems, Economic Evaluations, Quality of Life | Economics, Econometrics and Finance | 1,582 |
| 5 | Analytical Methods in Pharmaceuticals | Chemistry | 1,561 |

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

## Cite this page

Scholar4AI. (2026). Merck & Co., Inc., Rahway, NJ, USA (United States). Journal and Conference Research Rankings. Retrieved November 4, 2026, from https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states

```bibtex
@misc{scholar4ai-companies-merck-co-inc-rahway-nj-usa-united-states,
  author = {{Scholar4AI}},
  title = {Merck & Co., Inc., Rahway, NJ, USA (United States)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states}},
  urldate = {2026-11-04},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).